P46370 4th Annual Bioprocess and Technology 2018
Download Brochure Request

Register your interest

Comments

Register your interest

Comments

4th Annual Bioprocess and Technology 2018

31 October – 2 November 2018, One Farrer Hotel, Singapore

Book Now Download Brochure

SPECIAL 1-FOR-1 OFFER ON NORMAL RATES FOR PHARMACEUTICAL AND BIOTECH COMPANIES*
LIMITED SEATS, APPLICABLE ONLY TO 2-DAY MAIN CONFERENCE DAYS.
SEE PRICING BELOW FOR MORE INFORMATION.

overview

From the need to rethink innovation, to adopting disruptive manufacturing technology, the biopharma industry is pushing the boundaries of excellence. Will future of bioprocess be disease or epidemic based? What trends will determine new directions for industry? The 4th Annual Bioprocess and Technology is back with Pharma and technology partner insights on bioprocess management as a whole, and manufacturing trends.

“Bioprocess and Technology is a very unique event with focus in Bioprocess related information relevant for APAC. I highly recommend attending this conference.”
Anita R Patil, Group Leader, Wockhardt Research

Conference Highlights

  • Regional Biopharma Companies – Case Studies on Bioprocess Management, Vaccine Manufacturing, Operations, QA/AC
  • Continuous ManufacturingTechnology and Business Case, Conventional Batch-based Processing Vs. Continuous Manufacturing
  • Quality and Consistency Standards – Balancing Standards, Product Development Strategies, CGMP
  • Regulatory ClarityInterpretation, Guidelines for Biologics, Harmonisation, Disease Surveillance
  • Bioprocess Technology SpotlightManufacturing Trends, Capital Spending, Quality & Risk, and Facilities
  • CMO Showcase – Quality Standards, Six Sigma and Validation at Sites

Choose your language

Part of

Biopharma Development & Production Asia >>

Co-Located Events

Bioprocess and Technology >>
Biotech Investment Summit >>

agenda

8:00 am

Main Conference Registration and Morning Coffee

8:50 am

Chairperson’s Opening Remarks

Ken Yung, Professor and Associate Head, Department of Biology, Hong Kong Baptist University, Hong Kong

BIOPHARMA DEVELOPMENT AND PRODUCTION 2018 OPENING PLENARY SESSIONS

9:10 am

  • Translational research to understand local unmet medical need
  • Addressing ethnic difference through innovative science and development strategies
  • Contributing to collaborative R&D ecosystem to ensure quality

9:40 am

  • Analyzing latest biopharma trends and current unmet needs
  • Biopharma business models to capture market value
  • Lowering the cost-of-goods through cost-effective biomanufacturing strategies
  • Effectively forecasting market demand and managing drug supply to patients
  • Integrating entire biopharma value-chain for better speed to market

10:30 am

Morning Networking and Refreshment Break End of Plenary Session

11:20 am

Chairperson’s Opening Remarks

PROCESS INTENSIFICATION AND COST-REDUCTION STRATEGIES

11:30 am

12:00 pm

  • Technical CMC development for establishing an end-to-end bioprocess strategy
  • Process optimization and process intensification for better efficiency and speed to market
  • Developing an accelerated timeline for biologics development and bioproduction

12:30 pm

  • Growth in diversity of molecules entering the clinical pipeline and improving manufacturing productivity, flexibility, and cost efficiency
  • Implementing different processing tools and manufacturing approaches to achieve improved process outcomes
  • Discussion on existing and new single-use technologies with a focus on the benefits of choosing each processing tool with the goal of achieving desired outcomes

1:00 pm

Networking Lunch

CELL THERAPY AND NOVEL BIOTHERAPEUTICS DISCOVERY

2:00 pm

  • A technology platform for enabling the development of ADCs, bispecifics and multi-binding antibodies in versatile configurations
  • Lead identification and optimization for higher affinity and reduction in potential immunogenicity
  • Enabling higher therapeutic index through optimal disease target engagement

2:30 pm

  • Showcasing a patented nanotechnology for in-situ isolation of donor stem cells
  • Reducing the carcinogenic risk of cultivating NSCs through a specific nanotechnology matrix
  • Improving harvest yield, function and safety for individualized stem cell therapies

3:00 pm

  • Developing novel mAbs and innovative biotherapeutics through Science Based Drug Discovery (SBDD) and Market-Oriented Drug Development (MODD)
  • Accelerating bio-drug development via public-private partnership through KBIO
  • Raising efficiency of new drug development and commercialization

3:30 pm

Afternoon Networking & Refreshment Break

4:00 pm

  • Exploring regenerative effects of BDACs and their demonstrating pericytic identity
  • Engineering BDACs to meet clinical requirements on quantity and short-term availability
  • Designing bio-instructive biomaterials to support BDAC growth and proliferation

LARGE-SCALE CELL CULTURE SYSTEMS AND UPSTREAM OPTIMIZATION

4:30 pm

  • Importance of glycosylation on therapeutic protein
  • Altering the glycans on antibody to enhance efficacy
  • Increasing half-life of biologics through enhancement of specific glycans

5:00 pm

  • Managing commercial scale production for cell-derived biotherapeutics
  • Critical parameters to control, key factors to consider
  • In-process control methods for ensuring cell culture stability and product consistency

5:30 pm

Networking Cocktail

8:50 am

Chairperson’s Opening Remarks

OPTIMIZING VIRAL CLEARANCE AND IMPROVING RECOVERY YIELD

9:00 am

  • Overcoming filter fouling in viral clearance studies
  • Critical aspects in virus filtration
  • Comparison of different filter vendors

9:30 am

  • HCPs, DNA and other contaminants form the bulk of process-related impurities that arise from mAb bioproduction
  • Development of a single-use impurities depletion technology to be used under flow-through conditions and during clarification / polishing steps in downstream operations – Case study of implementation done by Sanofi
  • Envisioning its use in an optimized platform with process intensification possibilities or as a unique solution for sample preparation

10:00 am

  • Comparison of current cell harvesting and clarification strategies for mAbs
  • Analyzation of how cell culture parameters influencing the harvesting performance
  • Development of a harvesting guide to take the right way from the beginning to reduce time to market

10:30 am

Morning Networking & Refreshment Break

ANALYTICAL METHOD DEVELOPMENT AND CMC STRATEGIES

11:10 am

  • Critical concepts and MS strategies for analytical method development
  • Introduction of bioinformatics strategies to enable expedient glyco-analysis
  • Application of such strategies to therapeutic recombinant glycoprotein drugs

11:40 am

  • Applying CMC strategies for product development and better upstream & downstream process control
  • Ensuring a strong QbD and compliance focus with key stakeholders, partners and suppliers
  • Ongoing quality improvement and monitoring efforts for site operations
  • Overcoming the challenges for data integrity in line with regulatory requirements
  • Achieving process and manufacturing goals, including site certification

OPERATIONAL EXCELLENCE AND SMART FACILITIES OF THE FUTURE

12:30 pm

Bioprocess by Design – WuXi Biologics Experiences in Utilizing Single Use Technologies for Biologics Manufacturing Process Development

Liang Tang, Vice President of Biologics Development and Manufacturing, WuXi Biologics, China

1:00 pm

Networking Lunch

2:00 pm

  • Applying continuous process improvement activities in the biomanufacturing value-chain
  • Improving manufacturing operations through lean management approaches
  • Driving cost savings initiatives through deviation reduction initiatives

2:30 pm

  • Process change to maximize raw material yield and improve yield ratio
  • Enhancing operational efficiency and streamlining bioproduction processes
  • Lean management strategies for single-use systems and reduction in OPEX

3:00 pm

Afternoon Networking & Refreshment Break

3:30 pm

BIOPHARMA DEVELOPMENT AND PRODUCTION 2018 CLOSING PLENARY SESSIONS

4:00 pm

  • Reviewing latest disruptions in the biopharma industry
  • Re-thinking manufacturing productivity and quality
  • Connecting human resources, data, machines and networks for better outcomes
  • Impacts of Industry 4.0 on drug financing and investment outlook
  • Data management, product traceability and supply chain security

5:00 pm

Chairperson’s Summary and End of Main Conference Day Two

9:00 am

The workshop will give an overview on viral clearance principles and global regulatory requirements for all biopharmaceuticals like recombinants, vaccines, plasma products and animal/human tissue derived biologics. Best approaches for viral clearance studies particularly for recombinant products will be detailed and discussed and the effectiveness of frequently analyzed virus inactivation- and virus removal steps will be described.

Key learning outcomes:

  • Background on viral clearance
  • The right viral clearance study design
  • Viral clearance effectiveness

1:00 pm

End of workshop

pricing

Packages Price
2 Day ConferenceSGD $2895Early Bird
Extras Price
Pre-conference workshop SGD $800

Early Bird Rate: Register & Pay by 7 September 2018

Special 1-for-1 Offer on Normal Rates for Pharmaceutical and Biotech Companies*
Limited seats, applicable only to 2-day main conference days.
Email register@ibcasia.com.sg to find out more!

*The organizer reserves the right to determine the industry to which your company belongs, and to stop the promotion at any stage.

GROUP RATE: SGD 2,595
Register 2 Delegates and get 1 FREE PASS
Register 3 Delegates and get 2 FREE PASS
Register 5 Delegates and get 3 FREE PASS
(Group rate is based on normal rate of 2-day main conference package only)

For Group Registrations of more than 3 team members,
email info@ibcasia.com.sg or call +65 6508 2477

  • Multiple Bookings Discount pricing is applicable to groups of 3 or more delegates from the same organisation registering for the same event, at the same time.
  • Fee stated is the discounted price PER DELEGATE. Only one discount applies; either the early bird rate OR group rate.
  • All fees stated include luncheons, refreshments and complete set of documentation. It does not include the cost of accommodation and travel.
  • All delegates from Singapore-based companies are required to pay an additional 7% GST (SINGAPORE EVENTS ONLY)

Sponsorship

Partnership and Profile Building Opportunities are Now Available!
Contact us today to find out how you can position your company as a market leader at this event, and to explore the range of branding and marketing opportunities available.

View Sponsors and Exhibitors profile >>

speakers

Ken Yung 4th Annual Bioprocess and Technology 2018

Ken Yung

Professor and Associate Head, Department of Biology, Hong Kong Baptist University, Hong Kong

Ming-Qiang Zhang 4th Annual Bioprocess and Technology 2018

Ming-Qiang Zhang

Vice-President, Research & Development, Amgen, China

Dr. Carl Firth 4th Annual Bioprocess and Technology 2018

Dr. Carl Firth

Founder and Chief Executive Officer, Aslan Pharmaceuticals Pte Ltd, Singapore

Piers Ingram 4th Annual Bioprocess and Technology 2018

Piers Ingram

Chief Executive Officer, Hummingbird Bioscience, Singapore

Frank Ye

Senior Vice President, Technical Operations, Hangzhou JUST Biotherapeutics, China

Subhasis Banerjee 4th Annual Bioprocess and Technology 2018

Subhasis Banerjee

Associate Director, Manufacturing Sciences & Technology, MERCK

Per Karlberg

Business Leader Customized Bioprocess Solutions, GE Healthcare Life Sciences

Art Hsing-Mao Chu 4th Annual Bioprocess and Technology 2018

Art Hsing-Mao Chu

Director of Research, Immunework, Taiwan

Daeyoung Kim 4th Annual Bioprocess and Technology 2018

Daeyoung Kim

Principal Researcher, Division of Discovery & Optimization, New Drug Development Center, Osong Medical Innovation Foundation (KBIO), Korea

Anna Maria Blocki 4th Annual Bioprocess and Technology 2018

Anna Maria Blocki

Assistant Professor, Institute for Tissue Engineering and Regenerative Medicine (ITERM), Hong Kong

Pao Chun Lin 4th Annual Bioprocess and Technology 2018

Pao Chun Lin

Associate Staff Scientist, Bioprocessing Technology Institute, Singapore

Praveen Gupta 4th Annual Bioprocess and Technology 2018

Praveen Gupta

Head of Upstream Process Development, Mammalian & Microbial, Biosimilars, Intas, India

Horst Ruppach 4th Annual Bioprocess and Technology 2018

Horst Ruppach

Scientific Director Viral Pathogen Safety, Charles River, Germany

Fabien Rousset 4th Annual Bioprocess and Technology 2018

Fabien Rousset

Head of Bioseperations Business Unit, Daicel Bioseparations, France

Silke Bergheim-Pietza

Global Product Manager Pre- and Depth Filtration, Pall Biotech

Terry Nguyen-Khuong 4th Annual Bioprocess and Technology 2018

Terry Nguyen-Khuong

Associate Staff Scientist, Bioprocessing Technology Institute, Singapore

Venu Mallavarapu 4th Annual Bioprocess and Technology 2018

Venu Mallavarapu

Head, Operational Excellence, Lonza, Singapore

Christian Cater 4th Annual Bioprocess and Technology 2018

Christian Cater

Head of Operational Excellence, Roche, Singapore

Liang Tang 4th Annual Bioprocess and Technology 2018

Liang Tang

Vice President of Biologics Development and Manufacturing, WuXi Biologics, China

when & where

31 Oct - 02 Nov 2018

One Farrer Hotel
1 Farrer Park Station Road
Singapore 217562

Contact Person: Daniel Koh
DDI: (+65) 6705 7884
Fax: (+65) 6834 7892
Cell: (+65) 86870123
Email: danielkoh@onefarrer.com

contact

Still have a question?

Speaking Opportunities
Siang Yee
+65-6508 2446
SiangYee.Yeo@ibcasia.com.sg

Sponsorship Opportunities
Yvonne Leong
+65 6508 2489

Yvonne.Leong@ibcasia.com.sg

Media & Association Partnership Opportunities
Cloud He
+65 6508 2423
cloud.he@ibcasia.com.sg

sponsors

Partners

Supporting Association

STAY UPDATED ON OUR NEWS & EVENTS

IBC Asia is Singapore's leading event organiser. We conceive, develop and promote our own B2B industry conferences and corporate training courses, and offer tailored managed event solutions.

Find out more